Pharmacological characterization of the human P2Y13 receptor

Molecular Pharmacology

Volumn 64, Issue 1, 2003, Pages 104-112

  Marteau, Frederic ^a   Le Poul, Emmanuel ^c   Communi, David ^a   Communi, Didier ^a   Labouret, Catherine ^d   Savi, Pierre ^d   Boeynaems, Jean Marie ^a,b   Gonzalez, Nathalie Suarez ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Euroscreen SA   (Belgium)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PROPYLTHIO) 5' ADENYLIC ACID; 2 METHYLTHIOADENOSINE TRIPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 6 N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)ADENOSINE PHOSPHATE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AR 69931MX; AR C67085MX; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CLOPIDOGREL; CYCLIC AMP; DIADENOSINE TETRAPHOSPHATE; DICHLOROMETHYLENEBIS(PHOSPHONIC ACID); FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INOSITOL TRISPHOSPHATE; NUCLEOTIDE; PERTUSSIS TOXIN; PHOSPHONIC ACID DERIVATIVE; PROPANEDIOL DERIVATIVE; PURINE P2 RECEPTOR; PURINE P2Y RECEPTOR; PURINE P2Y12 RECEPTOR; PURINE P2Y13 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING KINETICS; CHO CELL; COMPETITIVE INHIBITION; DEGRADATION KINETICS; DRUG POTENCY; ENZYME REGULATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURINE SYNTHESIS; RECEPTOR BINDING; RECEPTOR UPREGULATION; SEQUENCE HOMOLOGY;

EID: 0037899612     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.1.104     Document Type: Article

References (33)

1. 6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate. Br J Pharmacol 124:1-3.
2. Brooker G, Harper JF, Terasaki WL, and Moylan RD (1979) Radioimmunoassay of cyclic AMP and cyclic GMP. Adv Cyclic Nucleotide Res 10:1-33.
3. i. J Biol Chem 276:41479-41485.
4. Communi D, Janssens R, Robaye B, Zeelis N, and Boeynaems JM (2000) Rapid up-regulation of P2Y messengers during granulocytic differentiation of HL-60 cells. FEBS Lett 475:39-42.
5. Communi D, Paindavoine P, Place GA, Parmentier M, and Boeynaems JM (1999) Expression of P2Y receptors in cell lines derived from the human lung. Br J Pharmacol 127:562-568.
6. Communi D, Pirotton S, Parmentier M, and Boeynaems JM (1995) Cloning and functional expression of a human uridine nucleotide receptor. J Biol Chem 270:30849-30852.
7. - transport. J Biol Chem 274:26461-26468.
8. Erb L, Garrad R, Wang Y, Quinn T, Turner JT, and Weisman GA (1995) Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270, 4185-4188.
9. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, and Koller BH (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5:1199-1202.
10. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, et al. (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Investig 107, 1591-1598.
11. Hechler B, Vigne P, Leon C, Breittmayer JP, Gachet C, and Frelin C (1998) ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53:727-733.
12. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (Lond) 409:202-207.
13. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, et al. (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42:213-220.
14. Kotani M, Mollereau C, Detheux M, Le Poul E, Brezillon S, Vakili J, Mazarguil H, Vassart G, Zajac JM, and Parmentier M (2001) Functional characterization of a human receptor for neuropeptide FF and related peptides. Br J Pharmacol 133:138-144.
15. Kukkonen JP, Nasman J, and Akerman KE (2001) Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response. Trends Pharmacol Sci 22:616-622.
16. Leff P, Scaramellini C, Law C, and McKechnie K (1997) A three-state receptor model of agonist action. Trends Pharmacol Sci 18:355-362.
17. 1 receptor-null mice. J Clin Investig 104, 1731-1737.
18. Ni H, Capodici J, Cannon G, Communi D, Boeynaems JM, Kariko K, and Weissman D (2002) Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-α secretion and signaling through a nucleotide receptor. J Biol Chem 277:12689-12696.
19. Palmer RK, Boyer JL, Schachter JB, Nicholas RA, and Harden TK (1998) Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol 54:1118-1123.
20. Park HS and Hourani SM (1999) Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5-diphosphate (ADP) in human platelets. Br J Pharmacol 127:1359-1366.
21. Patel K, Barnes A, Camacho J, Paterson C, Boughtflower R, Cousens D, and Marshall F (2001) Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. Eur J Pharmacol 430:203-210.
22. Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
23. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379-383.
24. 3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772-777.
25. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896.
26. 1 receptor. Mol Pharmacol 60:432-439.
27. 1 is required to inhibit platelet aggregation in whole blood under flow. Blood 98, 3340-3345.
28. von Kugelgen I and Wetter A (2000) Molecular pharmacology of P2Y-receptors. Naunyn Schmiedeberg's Arch Pharmacol 362:310-323.
29. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, and Robaye B (2001) The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol 166, 7172-7177.
30. Wittenberger T, Schaller HC, and Hellebrand S (2001) An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. J Mol Biol 307:799-813.
31. Zamecnik PC, Kim B, Gao MJ, Taylor G, and Blackburn GM (1992) Analogues of diadenosine 5′, 5‴-P1, P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA 89, 2370-2373.
32. Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, et al. (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276:8608-8615.
33. 13: identification and characterization of a novel Gαi-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther 301:705-713.